Thursday, September 02, 2010

Feedback| Helpdesk |Sign up| Login

 EDITORIAL
BLOW TO STEM CELL RESEARCH
past editorials ...
SERVICES
PHARMA TENDERS & PROJECTS
Tenders&Enquiries
Pharma Projects- NEW
CORPORATE
Company Profiles
Corporate Results
Corporate X-ray
Pharmabiz Studies of Top Companies
Indian Cos Approved by Intl Regulatory Agencies
US FDA UPDATE
US FDA: ANDA
US FDA: Warnings
US FDA: Approved NMEs upto December 2009
US FDA: New Approvals
US approved Labs with Stem Cell Lines
EXPORT & IMPORT
Drug Export Procedures
Drug Registration Norms for Various Countries
Drug Units With WHO GMP Certification
Pharma Export Data
Import Reg Update
PHARMA LAWS & DOCUMENTS
Notifications
Pharma Regulations
Patent Laws and Amendments
Patent Scan
Documents
New Drug Approvals
Notified Prices
List of banned FDCs w.e.f. 01.01.2002
List of formulations containing PPA
List of FDCs of Rifampicin + Isoniazid
LIST OF LABS & GOVT. BODIES
Govt Recognised In-House R&D Units
AICTE Boards & Committees
List of Indian CROs
List of CROs (International)
Govt & approved labs of India

SPECIAL FEATURES
Features
Business of PHARMA MARKETING

 INTERVIEW
DCA to beef up activities
R P Meena IPS, Director General of Drugs & Copyrights

past interviews ...
  International

EU recommends Rebif new formulation for MS patients


Monday, July 02, 2007 09:00 IST
Darmstadt

Merck KGaA, CHMP, EMEA, Rebif,interferon beta-1a, multiple sclerosis Merck Serono, immunogenicity,



Read complete story ...
(You will need to login first to read this story.)

Post a Comment

Comments Module

E-mail this article!

Printer friendly!

             
  Google Feeder   My Yahoo Feeder   Bloglines Feeder  
             


 









FORTHCOMING EVENTS
International
Domestic

CHRONICLE PHARMABIZ SPECIALS
Forthcoming
Past


 
CORPORATE
Pharma Stocks
Executive Diary
Pharma People
Product Launches

PHARMA MART
Buyer's Postings
Flash Sales Offer
Used Equipment
Contract Manufacturing
Surplus Inventory


 

Copyright © Saffron Media Pvt. Ltd.
Designed & Maintained by Fast Cursor